Joseph Gligorov, MD, PhD

Articles

Novel Treatment Approaches Under Investigation for HER2+ mBC

November 23rd 2023

Joseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.

Treatment Approaches for Patients With HER2+ mBC and Brain Metastases

November 16th 2023

Dr Joseph Gligorov discusses the management of brain metastases in patients with HER2-positive breast cancer, emphasizing tucatinib and trastuzumab as promising options.

Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC

November 16th 2023

Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.

French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC

November 9th 2023

Dr Gligorov underscores the significance of real-world data in France supporting the effectiveness of tucatinib and trastuzumab in combination for patients with heavily pretreated HER2+ metastatic breast cancer, with notable benefits even in cases with brain metastasis.

Treatment Sequencing Approaches for Patients With HER2+ mBC

November 9th 2023

Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.

Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment

November 2nd 2023

Joseph Gligorov, MD, reviews advances in the treatment of advanced HER2+ breast cancer, shares his global perspective, and explains how ESMO and NCCN guidelines are similar.

Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)

November 2nd 2023

Dr Joseph Gligorov highlights the impact of trastuzumab deruxtecan in treating HER2-positive breast cancer due to its impressive results in progression-free survival and overall survival, emphasizing its importance in early treatment, while acknowledging the need to monitor safety issues.

Dr. Gligorov on Potential Challenges of Utilizing PARP Inhibitors in TNBC

September 17th 2020

Joseph Gligorov, MD, PhD, discusses potential challenges of utilizing PARP inhibitors in triple-negative breast cancer.